“由于現(xiàn)今需要通過外部網(wǎng)絡(luò)研究來滿足關(guān)鍵業(yè)務(wù)問題，因此BT在生命科學研發(fā)中的強健的云服務(wù)就顯得至關(guān)重要，”BT全球服務(wù)部制藥和化工領(lǐng)域總裁Bas Burger說，“Accelrys HEOS同其它用于外部化研究的Accelrys應(yīng)用軟件結(jié)合起來成為BT生命科學研發(fā)中的一部分，這樣可使工作在制藥和生物技術(shù)公 司，以及學術(shù)界和政府科研的科學家們都能夠在云環(huán)境中高效協(xié)作。此平臺旨在讓客戶遵循該行業(yè)嚴格的安全、監(jiān)管和合規(guī)要求。”

　　作為Accelrys外部化協(xié)作套件的一部分，Accelrys HEOS證明了軟件即服務(wù)(SaaS)工作平臺可加速協(xié)同合作的藥物發(fā)現(xiàn)。該系統(tǒng)提供安全、實時的云端數(shù)據(jù)訪問，可訪問的數(shù)據(jù)包括化學品注冊、生物測定結(jié)果、計算和可視化分析、安全評估和藥代動力學數(shù)據(jù)以及其他項目信息，這將大幅降低訪問這些材料信息所付出的努力和IT費用。由于所有知識產(chǎn)權(quán)都存儲在一個安全的、包含具體項目信息的信息倉庫內(nèi)，因此Accelrys HEOS能幫助制藥和生物技術(shù)公司、合同研究機構(gòu)、學術(shù)機構(gòu)以及其他有合作關(guān)系的研究組織訪問關(guān)鍵信息、分享結(jié)果并及時地做出正確決策。

　　應(yīng)用于生命科學研發(fā)領(lǐng)域的BT使用BT云計算技術(shù)已經(jīng)開發(fā)出一個安全的、被隔離的平臺。它允許科學家在silico工作流和數(shù)據(jù)管道中進行構(gòu)造和編排，以便識別新藥物靶點和候選藥物。該平臺，開始于2012年的BioIT World，，它使科學家們能夠創(chuàng)建全球化的項目組，并且使他們可以通過社交媒體工具進行協(xié)作。該生態(tài)系統(tǒng)允許科學家們安全地上傳文件、共享結(jié)果并通過IM進行交流，包括語音、視頻或者聊天。他們還可以在一個環(huán)境中分析結(jié)果，這個環(huán)境可以分割數(shù)據(jù)，并可以使用合格的硬件組件和制藥行業(yè)特定的工作流。

　　如想獲取更多有關(guān)Accelrys HEOS和Accelrys Externalized Collaboration Suite的信息，請訪問Accelrys公司官方網(wǎng)站。

　　關(guān)于Accelrys

　　Accelrys公司(NASDAQ: ACCL)，是系統(tǒng)提供科技創(chuàng)新生命周期管理軟件領(lǐng)域的領(lǐng)導者，支持行業(yè)和組織依靠科技創(chuàng)新來提升自身競爭力。行業(yè)領(lǐng)先的Accelrys企業(yè)平臺，提供廣泛而靈活的科學解決方案，優(yōu)化整合科學的多樣性、實驗過程以及在研發(fā)、生產(chǎn)、工藝放大早期生產(chǎn)階段產(chǎn)品開發(fā)過程的信息需求。通過在建模與仿真、企業(yè)級實驗室管理、工作流和自動化方面的應(yīng)用程序、數(shù)據(jù)管理及信息學方面的整合能力，Accelrys使得科學創(chuàng)新者以前所未有的方式訪問、組織、分析并分享，最終提高創(chuàng)新能力，提高生產(chǎn)率和合規(guī)性，降低成本并加速從實驗室到市場的時間。

　　Accelrys解決方案應(yīng)用于1300多家公司，涉及制藥、生物技術(shù)、能源、化學、航空航天、快速消費品和工業(yè)產(chǎn)品等行業(yè)。Accelrys總部位于美國加利福尼亞州圣迭戈，員工包括200多名具有博士學位的科學家。如想了解更多關(guān)于Accelrys的公司的信息，您可以訪問公司網(wǎng)站 www.accelrys.com。

　　關(guān)于BT

　　BT是世界領(lǐng)先的通信服務(wù)和解決方案供應(yīng)商之一，客戶遍布170多個國家，其主要業(yè)務(wù)包括：提供全球網(wǎng)絡(luò)IT服務(wù);提供地方、國家及國際電信服務(wù)，滿足在家中、工作中以及在移動的用戶的使用需要;提供寬帶、互聯(lián)網(wǎng)產(chǎn)品與服務(wù)，以及聚集固定/移動的產(chǎn)品與服務(wù)。BT主要包括四個業(yè)務(wù)部門：BT全球服務(wù)部、BT零售部、BT批發(fā)部和Openreach。

　　2013年3月31日的財年會議上公布了BT集團的總收入為£18,897m，稅前利潤為£2,445m。英國電信公司(BT)是英國電信集團(BT Group)全資子公司，幾乎包括BT集團的所有業(yè)務(wù)和資產(chǎn)。英國電信集團已分別在倫敦和紐約的證券交易所上市。如想了解更多相關(guān)信息，您可以訪問BT公司網(wǎng)站www.btplc.com。

　　附英文原文

　　Accelrys HEOS® Goes Live on BT Cloud Environment

　　Industry-leading research collaboration workspace within Accelrys Externalized Collaboration Suite moves to secure, reliable, scalable cloud infrastructure

　　BOSTON, April 9, 2013 /PRNewswire/ -- Bio-IT World -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that the cloud-based Accelrys HEOS® information management and collaboration workspace is now live on BT for Life Sciences R&D cloud platform. BT for Life Sciences R&D provides a secure, reliable and scalable cloud environment for HEOS users, enabling more efficient and productive networked collaboration by pharmaceutical research organizations and their partners. The latest engagement between BT and Accelrys furthers the relationship on hosting and externalization that has been in place between the companies since April 2012, while strengthening the enterprise capabilities of the Accelrys Externalized Collaboration Suite announced today at Bio-IT World. Combined with the enterprise cloud infrastructure provided by BT, the Accelrys Externalized Collaboration Suite addresses the needs of research organizations transitioning to an externalized network research environment.

　　"With the pharmaceutical industry moving rapidly to a network research model, organizations are struggling to provide secure, real-time information exchange and IP protection across externalized networks," said Dr. Matt Hahn, senior vice president and chief technology officer, Accelrys. "Accelrys and BT recognize the need for drug discovery research organizations to collaborate effectively within a secure, reliable, global cloud infrastructure as they move to this new model."

　　"BTs robust Life Sciences for R&D cloud service is essential to meeting the critical business issues raised by externalized network research today," said Bas Burger , president of Global Pharmaceutical & Chemical for BT Global Services. "Combining Accelrys HEOS and other Accelrys applications for externalized research as part of BT for Life Sciences R&D enables scientists working in pharmaceutical and biotechnology companies, as well as academia and government, to collaborate effectively in a cloud environment. The platform is designed to allow customers to comply with the industrys stringent security, regulatory and compliance requirements."

　　As part of the Accelrys Externalized Collaboration Suite, Accelrys HEOS is a proven Software-as-a-Service (SaaS) workspace that accelerates collaborative drug discovery. The system provides secure, real-time cloud access to data about such things as chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information. This material can be accessed with greatly reduced effort and IT overhead. Accelrys HEOS enables pharmaceutical and biotechnology companies, contract research organizations, academic institutions and other partnering research organizations to access critical information, share results and make informed decisions in a timely manner with all IP stored in a secure, project-specific information warehouse.

　　BT for Life Sciences R&D was developed as a secure and segregated platform, using BT Cloud Compute. It allows scientists to construct and orchestrate in silico workflows and data pipelines so that new pharmaceutical targets and drug candidates can be identified. This platform, launched at BioIT World 2012, enables research scientists to create global project groups and collaborate using social media tools. This ecosystem allows them to securely upload documents, share results and communicate via IM, voice, video or chat. They can also analyze results in an environment that segments data and uses qualified hardware components and workflows specific to the pharmaceutical industry.

　　Refer to the Accelrys website for more information on Accelrys HEOS and the Accelrys Externalized Collaboration Suite.

　　About Accelrys, Inc.

　　Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

　　Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

　　About BT

　　BT is one of the worlds leading providers of communications services and solutions, serving customers in more than 170 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband and internet products and services and converged fixed/mobile products and services. BT consists principally of four lines of business: BT Global Services, BT Retail, BT Wholesale and Openreach.

　　In the year ended 31 March 2012, BT Groups revenue was £18,897m with profit before taxation of £2,445m.

　　British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on stock exchanges in London and New York.

　　For more information, visit www.btplc.com